Dr. Morency advises clients on the creation and development of cost-effective, strategic intellectual property (IP) portfolios. He also provides counseling to life science companies in patent interference, post-grant reviews, intellectual property enforcement, and litigation issues, as well as preparing patent invalidity, freedom to operate and non-infringement opinions. His legal experience encompasses numerous technologies such as neurobiology, stem cell and transgenic technologies, immunology and vaccine technologies, novel antibiotics, cancer therapeutics, tissue and organ regeneration, blood cells and blood products, drug delivery, drug discovery, gene therapy, genomics, proteomics, nanotechnologies, antioxidants, nutraceuticals and dietary supplement technologies, and medical devices.
In addition to the creation and management of IP portfolios and related counseling, Dr. Morency has extensive experience in the commercialization of IP, including the negotiation and drafting of transactional agreements for the transfer of intellectual property rights, such as IP licenses, material transfer agreements, strategic collaborations, mergers and acquisitions, as well as conducting due diligence related to various financings and transactions. This extensive experience representing large biopharmaceutical companies, investors, and underwriters provides Dr. Morency with a unique insight on creating IP portfolios that meet and exceeds the industry expectations, which enhances the technology’s valuation.
•09.04.18 / Events
Adler Pollock & Sheehan Hosts Life Science Startups in Southern New England
•Selected as a Massachusetts Super Lawyers 2004-2007.
•Over 20 scholarships, awards, and academic prizes, including a Licensing Executive Society (LES) Fellowship (1993-1994); a Medical Research Council (MRC) Studentship (1989-1991; ranked first overall in the national competition); and a Natural Sciences & Engineering Research Council Postgraduate Scholarship (1987-1989).
Seminars / Publications
•Moderator, presentation entitled, Legal and Business Strategies for Early-Stage Med Tech” MedMates 2nd Annual Life Sciences Expo 2018, April 2018.
•Guest lecturer, Biotechnology Graduate Course entitled “The Importance of Intellectual Property in Biotechnology” Brown University, Fall 2016 and Fall 2017.
•Invited Speaker, presentation entitled, “MassChallenge Case Study: Top IP Mistakes Made by Early Stage Technology Companies” MassChallenge Competition 2013, 2014, and 2015.
•Organizer and Moderator, presentation entitled, Getting the Most from Your IP Budget: Strategies for IP Portfolio Management and Litigation Avoidance Foley’s Executive Briefing Series, Boston, Massachusetts, September 2009.
•Invited Speaker, presentation entitled, Intellectual Property Strategies for Emerging Technology Companies MIT Entrepreneurs Luncheon Series, Massachusetts Institute of Technology, Cambridge, MA, June 2006, 2007, and 2008.
•Invited Speaker, presentation entitled, Intellectual Property Strategies for the Protection of Unique Food Products Foley’s Quarterly Food Industry Web Conference Series, October 2007.
•Invited Speaker, presentation entitled, From Idea to Effort to Operating Entity - An Entrepreneur's Guide Babson Entrepreneurship Program, Babson College, Babson Park, MA, May 2007, 2008, and 2009.
• How to Respond to a Cease and Desist Letter. NutraingredientUSA.com, J.F. Ewing, M. Flores, and M. Morency, February 2008.
• “Patently wise: What, how and where to patent.” NutraingredientUSA.com, M. Morency and J.F. Ewing, October, 2007.
• Preparing for impending USPTO rule changes. NutraIngredientUSA.com, J.F. Ewing and M. Morency, January 2007.
•“Preparing for a new round of impending US patent and trademark rule changes,” Mass High Tech, J.F. Ewing and M. Morency, September 2006.
•“Keeping trade secrets under wrap,” NutraIngredients-USA.com, J.F. Ewing, M. Morency, and S. Mollman Elliott, August 2006.
•“Preparing for a business transaction,” NutraIngredients-USA.com, J.F. Ewing and M. Morency, June 2006.
•“Preserving intellectual property before a patent is issued,” NutraIngredients-USA.com, J.F. Ewing and M. Morency, May 2006.
•“Nutraceuticals and functional foods require governance, present opportunity,” Mass High Tech, J.F. Ewing and M. Morency, October 3, 2005.
•“Knowledge generation, integration key in drug development strategies,” Mass High Tech, J.F. Ewing, J.M. Garvey, and M. Morency, July 6, 2004.
•“Rational Decisions: Rational-drug-design firms are now under patent scrutiny. But this is a good thing.” Bio IT World, J.M. Garvey and M. Morency, June 17, 2004.
•“Computationally-Guided Rational Drug Design: The Biotech Industry’s Rational Progression for New Drug Development,” Financier Worldwide / Biotechnology Sector Review, J.M. Garvey and M. Morency, June 2004, pp. 23 24.
•“Well-written IP strategy puts startups on roadmap for development,” Mass High Tech, J.M. Garvey and M. Morency, April 5, 2004.
•“Patent strategy can bring collaboration revenues,” Mass High Tech, M. Morency, J.F. Ewing, C. Pham, and J.M. Garvey, February 2, 2004.
•“Traps for the unwary,” Mass High Tech, M. Morency, J.F. Ewing, and J.M. Garvey, October 13, 2003.
•“How to get licensees to help you monitor the market for infringers,” PatentWorld, J.M. Garvey, J.F. Ewing, and M. Morency, October 13, 2003.
•Morency M., Quirion R., and Mishra R.K., Distribution of cholecystokinin receptors in the bovine brain: A quantitative autoradiographic study. Neuroscience, 1994 Sep; 62(1): 307 - 316.
•Srivastava L.K., Morency M., and Mishra R.K., Ontogeny of dopamine D 2 receptor mRNA in rat brain. Eur. J. Pharmacol., 1992 Feb 13; 225(2): 143 -150.
•Morency M., Quirion R., Nair N.P., and Mishra R.K., Localization of cholecystokinin binding sites in canine brain using quantitative autoradiography. Prog. Neuropsychopharmacol. Biol. Psychiatry,1991; 15(2): 291 -296.
•Srivastava L.K., Morency M., Bajwa S.B., and Mishra R.K., Effect of haloperidol on expression of dopamine D 2 receptor mRNAs in rat brain. J. Mol. Neurosci.,1990; 2(3): 155 -161.
•Morency M. and Mishra R.K., Cholecystokinin (CCK) receptors. In: Peptide Hormone Receptors, (M. Kalimi and M.H. Hubbard, eds). Walter de Gruyter, Berlin/New York, 1987 pp. 385-436.
•Morency M., Ross G.M., Hesketh D., and Mishra R.K., Effects of unilateral intracerebroventricular microinjections of cholecystokinin (CCK) on circling behavior of rats. Peptides,1987 Nov-Dec; 8(6): 989-995.
•Morency M., Stewart R.J., and Beninger R.J., Circling behavior following unilateral microinjections of cocaine into the medial prefrontal cortex: dopaminergic or local anesthetic effect? J. Neurosci.,1987 Mar; 7(3): 812-818.
•Beninger R.J., Cheng M., Hahn B.L., Hoffman D.C., Mazurski E.J., Morency M., Ramm P., and Stewart R.J., Effects of extinction, pimozide, SCH 23390, and metoclopramide on food-rewarded operant responding of rats. Psychopharmacology (Berl),1987; 92(3): 343-349.
•Morency M. and Beninger R.J., Dopaminergic substrates of cocaine-induced place conditioning. Brain Res., 1986 Dec 3; 399(1): 33-41.
•Stewart R.J., Morency M., and Beninger R.J., Differential effects of intrafrontocortical microinjections of dopamine agonists and antagonists on circling behavior of rats. Behav. Brain Res.,1985 Sep; 17(1): 67-72.
•Morency M., Stewart R.J., and Beninger R.J., Effects of unilateral microinjections of sulpiride into the medial prefrontal cortex on circling behavior of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry,1985; 9(5-6): 735-738.
You should not send any sensitive or confidential information through this site. Emails sent through this site do not create an attorney-client relationship and may not be treated as privileged or confidential. The lawyer or law firm you are contacting is not required to, and may choose not to, accept you as a client. The Internet is not necessarily secure and emails sent though this site could be intercepted or read by third parties.